| Literature DB >> 32331859 |
Kirsten M A Trayner1, Norah E Palmateer2, Sharon J Hutchinson2, David J Goldberg2, Samantha J Shepherd3, Rory N Gunson3, Emily J Tweed4, Saket Priyadarshi5, Harry Sumnall6, Amanda Atkinson6, Andrew McAuley2.
Abstract
BACKGROUND: To address rising drug-related harms (including significant transmission of HIV) among people who inject drugs (PWID) in Glasgow, officials have proposed the introduction of the UK's first drug consumption room (DCR) in Glasgow city centre. Using a nationally representative sample, this study aimed to determine willingness to use a DCR among PWID nationally, in Glasgow city centre (the proposed DCR location), other Scottish city centres (excluding Glasgow) and the rest of Scotland (excluding city centres).Entities:
Keywords: Drug consumption rooms; Harm reduction; People who inject drugs; Supervised injection facilities
Mesh:
Substances:
Year: 2020 PMID: 32331859 PMCID: PMC8063177 DOI: 10.1016/j.drugpo.2020.102731
Source DB: PubMed Journal: Int J Drug Policy ISSN: 0955-3959
Willingness to use a Drug Consumption Room (DCR) among 1469 PWID Scotland during 2017-18, stratified by Glasgow City Centre (proposed location of the first DCR), Scottish city centres and rest of Scotland, according to demographic factors, injecting risk behaviours, and drug-related harms, 2017–18.
| All Scotland | Glasgow city centre | Scotland city centres (excluding Glasgow) | Rest of Scotland (excluding city centres) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Willing to use a DCR | 95% CI | Willing to use a DCR | 95% CI | Willing to use a DCR | 95% CI | Willing to use a DCR | 95% CI | |||||
| 75% (1082/1442) | 73–77 | 83% (179/216) | 77–87 | N/A | 83% (184/223) | 77–87 | N/A | 72% (719/1003) | 69–74 | N/A | ||
| Male | 76% (817/1080) | 73–78 | 84% (154/184) | 77–88 | 81% (141/174) | 75–86 | 72% (522/722) | 69–75 | ||||
| Female | 73% (262/358) | 68–78 | 0.351 | 77% (24/31) | 60–89 | 0.392 | 88% (43/49) | 75–94 | 0.274 | 70% (195/278) | 65–75 | 0.498 |
| <35 | 77% (279/364) | 72–81 | 83% (30/36) | 68–92 | 85% (70/82) | 75–94 | 73% (179/246) | 67–78 | ||||
| 35–44 | 75% (563/752) | 72–77 | 86% (100/116) | 78–91 | 0.258 | 82% (90/110) | 74–88 | 71% (373/526) | 67–75 | |||
| 44+ | 74% (239/325) | 69–78 | 0.636 | 77% (49/64) | 64–85 | 77% (24/31) | 60–89 | 0.590 | 72% (166/230) | 66–78 | 0.851 | |
| Yes | 86% (340/394) | 83–89 | 87% (108/124) | 80–91 | 92% (72/78) | 84–96 | 83% (160/192) | 77–88 | ||||
| No | 71% (740/1046) | 68–73 | 77% (70/91) | 67–84 | 77% (112/145) | 70–83 | 69% (558/810) | 66–72 | ||||
| Yes | 76% (1005/1322) | 74–78 | 85% (157/184) | 80–90 | 85% (178/210) | 79–89 | 72% (670/928) | 69–75 | ||||
| No | 63% (74/117) | 54–71 | 69% (22/32) | 51–82 | 36% (4/11) | 15–64 | 65% (48/74) | 53–75 | 0.178 | |||
| Yes | 79% (353/446) | 75–83 | 84% (133/158) | 78–89 | 75% (24/32) | 58–87 | 77% (196/256) | 71–81 | ||||
| No | 73% (725/992) | 70–76 | 79% (46/58) | 67–88 | 0.400 | 84% (158/189) | 78–88 | 0.238 | 70% (521/745) | 67–73 | ||
| Yes | 87% (203/233) | 82–91 | 86% (87/101) | 78–92 | 95% (36/38) | 83–99 | 85% (80/94) | 77–91 | ||||
| No | 72% (877/1206) | 70–75 | 80% (92/115) | 72–86 | 0.232 | 80% (146/183) | 73–85 | 70% (639/908) | 67–73 | |||
| 0 | 66% (267/404) | 61–70 | 56% (10/18) | 34–75 | 71% (45/63) | 59–81 | 66% (212/323) | 60–71 | ||||
| 1 | 75% (377/501) | 71–79 | 88% (43/49) | 76–94 | 83% (72/87) | 74–89 | 72% (262/365) | 67–76 | ||||
| 2 | 80% (273/341) | 76–84 | 81% (57/70) | 71–89 | 90% (45/50) | 79–96 | 77% (171/221) | 71–82 | ||||
| 3, 4 or 5 | 85% (147/172) | 79–90 | 86% (63/73) | 77–92 | 95% (19/20) | 76–99 | 82% (65/79) | 72–89 | ||||
| Yes | 85% (35/41) | 72–93 | 92% (24/26) | 76–98 | 10–91 | 77% (10/13) | 50–92 | |||||
| No | 74% (967/1300) | 72–77 | 0.111 | 81% (153/188) | 75–86 | 0.167 | 77–88 | 0.218 | 71% (652/917) | 68–74 | 0.645 | |
| Yes | 77% (307/399) | 73–81 | 85% (79/93) | 76–91 | 88% (45/51) | 77–95 | 72% (183/255) | 66–77 | ||||
| No | 74% (613/825) | 72–77 | 0.316 | 83% (87/105) | 75–89 | 0.690 | 79% (98/124) | 71–85 | 0.152 | 72% (428/596) | 86–91 | 0.989 |
| Yes | 80% (210/261) | 75–85 | 82% (46/56) | 70–90 | 90% (46/51) | 79–96 | 77% (118/154) | 69–83 | ||||
| No | 74% (857/1160) | 71–76 | 83% (131/157) | 77–88 | 0.824 | 80% (133/166) | 73–86 | 0.098 | 71% (593/837) | 68–74 | 0.144 | |
| Yes | 78% (310/397) | 74–82 | 81% (63/78) | 71–88 | 83% (64/77) | 73–90 | 76% (183/242) | 70–81 | ||||
| No | 74% (772/1044) | 71–77 | 0.105 | 84% (116/138) | 77–89 | 0.538 | 81% (120/146) | 75–88 | 0.863 | 71% (536/760) | 67–74 | 0.125 |
May not add up due to missing data;
Derived from chi-squared test;
Missing values excluded from analysis;
Non-responses/missing data is only presented if it is greater than 5% of the total sample;
Comprised of the following risk factors: cocaine injecting, public injecting, sharing needles/syringes, high injecting frequency and re-using needle/syringes,
Chi-squared test for trend,
Data suppressed to prevent deductive disclosure.